A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

NCT02271217 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

377

Enrollment

INDUSTRY

Sponsor class

Conditions

Post-Ischemic Stroke

Interventions

DRUG: Placebo
DRUG: dalfampridine-ER 7.5mg
DRUG: dalfampridine-ER 10mg

Sponsor

Acorda Therapeutics